{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,29]],"date-time":"2025-05-29T04:12:39Z","timestamp":1748491959366,"version":"3.41.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2015,6,27]],"date-time":"2015-06-27T00:00:00Z","timestamp":1435363200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2015,9]]},"DOI":"10.1007\/s10096-015-2426-6","type":"journal-article","created":{"date-parts":[[2015,6,26]],"date-time":"2015-06-26T10:23:07Z","timestamp":1435314187000},"page":"1879-1884","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of and risk of bleeding during pegylated interferon plus ribavirin treatment in HIV\/HCV-coinfected patients with pretreatment thrombocytopenia"],"prefix":"10.1007","volume":"34","author":[{"name":"On behalf of the Grupo Andaluz para el Estudio de las Hepatitis V\u00edricas (HEPAVIR) de la Sociedad Andaluza de Enfermedades Infecciosas (SAEI)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Mira","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"Red de Investigaci\u00f3n en SIDA (RIS-HEP07)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Neukam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. F.","family":"L\u00f3pez-Cort\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rivero-Ju\u00e1rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"T\u00e9llez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Gir\u00f3n-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"de los Santos-Gil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Ojeda-Burgos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Merino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"R\u00edos-Villegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Collado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Torres-Cornejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Mac\u00edas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"P\u00e9rez-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. A.","family":"Pineda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,6,27]]},"reference":[{"issue":"Suppl 1","key":"2426_CR1","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1093\/infdis\/jis764","volume":"207","author":"MS Sulkowski","year":"2013","unstructured":"Sulkowski MS (2013) Current management of hepatitis C virus infection in patients with HIV co-infection. J Infect Dis 207(Suppl 1):S26\u2013S32","journal-title":"J Infect Dis"},{"key":"2426_CR2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1177\/135965350701200402","volume":"12","author":"V Soriano","year":"2007","unstructured":"Soriano V, Miralles C, Berd\u00fan MA et al (2007) Premature treatment discontinuation in HIV\/HCV-coinfected patients receiving pegylated interferon plus weight-based ribavirin. Antivir Ther 12:469\u2013476","journal-title":"Antivir Ther"},{"key":"2426_CR3","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1093\/jac\/dkm373","volume":"60","author":"JA Pineda","year":"2007","unstructured":"Pineda JA, Mira JA, Gil de los Santos I et al (2007) Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus\/HIV-coinfected patients. J Antimicrob Chemother 60:1347\u20131354","journal-title":"J Antimicrob Chemother"},{"key":"2426_CR4","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S1473-3099(13)70149-X","volume":"13","author":"M Sulkowski","year":"2013","unstructured":"Sulkowski M, Pol S, Mallolas J et al (2013) Boceprevir versus placebo with pegylated interferon alfa-2b and ribavirin for treatment of hepatitis C virus genotype 1 in patients with HIV: a randomised, double-blind, controlled phase 2 trial. Lancet Infect Dis 13:597\u2013605","journal-title":"Lancet Infect Dis"},{"key":"2426_CR5","doi-asserted-by":"crossref","first-page":"86","DOI":"10.7326\/0003-4819-159-2-201307160-00654","volume":"159","author":"MS Sulkowski","year":"2013","unstructured":"Sulkowski MS, Sherman KE, Dieterich DT et al (2013) Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial. Ann Intern Med 159:86\u201396","journal-title":"Ann Intern Med"},{"key":"2426_CR6","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa040842","volume":"351","author":"FJ Torriani","year":"2004","unstructured":"Torriani FJ, Rodr\u00edguez-Torres M, Rockstroh JK et al (2004) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351:438\u2013450","journal-title":"N Engl J Med"},{"key":"2426_CR7","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1001\/jama.292.23.2839","volume":"292","author":"F Carrat","year":"2004","unstructured":"Carrat F, Bani-Sadr F, Pol S et al (2004) Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 292:2839\u20132848","journal-title":"JAMA"},{"key":"2426_CR8","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1056\/NEJMoa032653","volume":"351","author":"RT Chung","year":"2004","unstructured":"Chung RT, Andersen J, Volberding P et al (2004) Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 351:451\u2013459","journal-title":"N Engl J Med"},{"key":"2426_CR9","doi-asserted-by":"crossref","first-page":"F27","DOI":"10.1097\/00002030-200409030-00003","volume":"18","author":"M Laguno","year":"2004","unstructured":"Laguno M, Murillas J, Blanco JL et al (2004) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV\/HCV co-infected patients. AIDS 18:F27\u2013F36","journal-title":"AIDS"},{"key":"2426_CR10","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1111\/j.1478-3231.2012.02798.x","volume":"32","author":"EG Giannini","year":"2012","unstructured":"Giannini EG, Marenco S, Fazio V et al (2012) Peripheral blood cytopaenia limiting initiation of treatment in chronic hepatitis C patients otherwise eligible for antiviral therapy. Liver Int 32:1113\u20131119","journal-title":"Liver Int"},{"key":"2426_CR11","unstructured":"Pegasys (peginterferon alfa-2a) (2011) Full prescribing information. South San Francisco, CA"},{"key":"2426_CR12","unstructured":"Pegintron (peginterferon alfa-2b) (2012) Full prescribing information. Whitehouse Station, NJ"},{"key":"2426_CR13","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jhep.2013.11.003","volume":"60","author":"European Association for Study of Liver","year":"2014","unstructured":"European Association for Study of Liver (2014) EASL Clinical Practice Guidelines: management of hepatitis C virus infection. J Hepatol 60:392\u2013420","journal-title":"J Hepatol"},{"key":"2426_CR14","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1053\/j.gastro.2006.11.011","volume":"132","author":"ML Shiffman","year":"2007","unstructured":"Shiffman ML, Ghany MG, Morgan TR et al (2007) Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 132:103\u2013112","journal-title":"Gastroenterology"},{"key":"2426_CR15","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1177\/135965350701200805","volume":"12","author":"JA Mira","year":"2007","unstructured":"Mira JA, L\u00f3pez-Cort\u00e9s LF, Merino D et al (2007) Predictors of severe haematological toxicity secondary to pegylated interferon plus ribavirin treatment in HIV-HCV-coinfected patients. Antivir Ther 12:1225\u20131235","journal-title":"Antivir Ther"},{"key":"2426_CR16","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1086\/656235","volume":"51","author":"JA Pineda","year":"2010","unstructured":"Pineda JA, Caruz A, Rivero A et al (2010) Prediction of response to pegylated interferon plus ribavirin by IL28B gene variation in patients coinfected with HIV and hepatitis C virus. Clin Infect Dis 51:788\u2013795","journal-title":"Clin Infect Dis"},{"key":"2426_CR17","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/0168-8278(91)90084-O","volume":"13","author":"PJ Scheuer","year":"1991","unstructured":"Scheuer PJ (1991) Classification of chronic viral hepatitis: a need for reassessment. J Hepatol 13:372\u2013374","journal-title":"J Hepatol"},{"key":"2426_CR18","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1086\/521857","volume":"45","author":"S Vergara","year":"2007","unstructured":"Vergara S, Mac\u00edas J, Rivero A et al (2007) The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 45:969\u2013974","journal-title":"Clin Infect Dis"},{"key":"2426_CR19","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1093\/cid\/cis779","volume":"55","author":"JA Mira","year":"2012","unstructured":"Mira JA, Garc\u00eda-Rey S, Rivero A et al (2012) Response to pegylated interferon plus ribavirin among HIV\/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Clin Infect Dis 55:1719\u20131726","journal-title":"Clin Infect Dis"},{"key":"2426_CR20","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.jhep.2010.04.013","volume":"53","author":"R Roomer","year":"2010","unstructured":"Roomer R, Hansen BE, Janssen HL et al (2010) Thrombocytopenia and the risk of bleeding during treatment with peginterferon alfa and ribavirin for chronic hepatitis C. J Hepatol 53:455\u2013459","journal-title":"J Hepatol"},{"key":"2426_CR21","first-page":"131","volume":"9","author":"N Merchante","year":"2007","unstructured":"Merchante N, Jim\u00e9nez-S\u00e1enz M, Pineda JA (2007) Management of HCV-related end-stage liver disease in HIV-coinfected patients. AIDS Rev 9:131\u2013139","journal-title":"AIDS Rev"},{"key":"2426_CR22","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/hep.25616","volume":"56","author":"N Merchante","year":"2012","unstructured":"Merchante N, Rivero-Ju\u00e1rez A, T\u00e9llez F et al (2012) Liver stiffness predicts clinical outcome in human immunodeficiency virus\/hepatitis C virus-coinfected patients with compensated liver cirrhosis. Hepatology 56:228\u2013238","journal-title":"Hepatology"},{"key":"2426_CR23","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1086\/605676","volume":"49","author":"JA Pineda","year":"2009","unstructured":"Pineda JA, Aguilar-Guisado M, Rivero A et al (2009) Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 49:1274\u20131282","journal-title":"Clin Infect Dis"},{"key":"2426_CR24","doi-asserted-by":"crossref","first-page":"2227","DOI":"10.1056\/NEJMoa073255","volume":"357","author":"JG McHutchison","year":"2007","unstructured":"McHutchison JG, Dusheiko G, Shiffman ML et al (2007) Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. N Engl J Med 357:2227\u20132236","journal-title":"N Engl J Med"},{"key":"2426_CR25","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1097\/MEG.0b013e328357d5f2","volume":"24","author":"CS Voican","year":"2012","unstructured":"Voican CS, Naveau S, Perlemuter G (2012) Successful antiviral therapy for hepatitis C virus-induced cirrhosis after an increase in the platelet count with romiplostim: two case reports. Eur J Gastroenterol Hepatol 24:1455\u20131458","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2426_CR26","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1007\/s00277-012-1659-z","volume":"92","author":"N Taylor","year":"2013","unstructured":"Taylor N, Melchardt T, Grundbichler M et al (2013) Use of romiplostim allows for hepatitis C therapy in a HIV\/HCV coinfected patient. Ann Hematol 92:1001\u20131002","journal-title":"Ann Hematol"},{"key":"2426_CR27","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/j.gastro.2013.10.012","volume":"146","author":"NH Afdhal","year":"2014","unstructured":"Afdhal NH, Dusheiko GM, Giannini EG et al (2014) Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy. Gastroenterology 146:442\u2013452.e1","journal-title":"Gastroenterology"}],"container-title":["European Journal of Clinical Microbiology & Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-015-2426-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10096-015-2426-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-015-2426-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,28]],"date-time":"2025-05-28T21:49:39Z","timestamp":1748468979000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10096-015-2426-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,6,27]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2015,9]]}},"alternative-id":["2426"],"URL":"https:\/\/doi.org\/10.1007\/s10096-015-2426-6","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"type":"print","value":"0934-9723"},{"type":"electronic","value":"1435-4373"}],"subject":[],"published":{"date-parts":[[2015,6,27]]}}}